Erythropoietin in the human body is a hormone like substance secreted by the kidneys and liver, which can promote red blood cell production. Erythropoietin can increase blood flow specific solubility (increase the percentage of red blood cells in the blood) in patients with kidney disease anemia. EPO stimulants are artificially synthesized based on the principle of erythropoietin, which can promote the generation of oxygen in muscles, thereby making muscles stronger and working longer. Agents promoting the synthesis of red blood cells are known as erythropoiesis stimulating agents.
Erythropoiesis stimulating agents recommended for the treatment of anemia. Erythropoietin (EPO) is an essential hematopoietic growth factor for red blood cell proliferation, differentiation, and maintenance of standard numbers of peripheral circulating red blood cells in the body.
Global Erythropoiesis Stimulating Agents Market expected to grow with a CAGR of 10.3% during the predicted period, 2019-2027, and projected to generate revenue over USD 12.5 Billion by 2020. The rise in the incidence of anemia cases worldwide is likely to robust the growth of the global Erythropoiesis Stimulating Agents market in the estimated period. Additionally, the rising awareness about erythropoiesis stimulating agent therapies across the globe leads to the growth of the global Erythropoiesis Stimulating Agents market. Moreover, the surge in demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin is estimated to drive the global Erythropoiesis Stimulating Agents market in the upcoming periods.
As per the World Health Organization, anemia is among the several complications of chronic kidney disease, with a prevalence of about 15% in the United States. More than 50% of patients with advanced disease develop anemia. Further, the growing incidence of chronic kidney disease worldwide is propelling an exponential growth in the global Erythropoiesis Stimulating Agents market in the future timeline. According to WHO 2015 study estimated that 1.2 million people died from kidney failure, an increase of 32% since 2005. Additionally, each year, around 1.7 million people die from acute kidney injury. Overall, about 5–10 million people die annually from kidney disease.
Besides, an increase in the number of new cancer cases and the rapid surge in tumor disease expected to accelerate the global Erythropoiesis Stimulating Agents market. The World Health Organization expects the number of cases related to cancer will increase by 70%, from 14 million in 2012 to 18.1 million in 2018 and 24 million by 2035.
The global incidence of chronic kidney disease has increased dramatically, and chronic kidney disease has become a public health problem across the globe. Changes in age and epidemiological trends have significantly increased the incidence of chronic kidney disease worldwide. According to WHO, the global prevalence of chronic kidney disease (CKD) increased by 88.76%, the prevalence increased by 86.95%, and deaths.
The increasing number of new cancer cases and prolonging survival time will increase the number of patients. Globally, malignant tumors are a threat to human health. The incidence of tumor-associated anemia is as high as 60% Cancer-related anemia (CRA). Anemia that occurs during development and treatment is one of the common concomitant diseases of malignant tumors.
Erythropoiesis Stimulating Agents increase the number of red blood cells, used for anemia, tissue separation, premature babies, used in cancer and hematology. The demand for erythropoiesis stimulating agents is rapidly increasing due to the rising prevalence of chronic kidney disease, cancer, and the growing demand for cheaper erythropoietin drugs.
Based on Product Type, the global Erythropoiesis Stimulating Agents Market categorized into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta, and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta). The Epoetin Alfa segment projected to lead the market, owing to the augmentation in demand of Epoetin Alfa for treatment of anemia (low red blood cell count) in people with chronic kidney failure, and people are receiving chemotherapy. Darbepoetin Alfa will drive by more number of approved products for prescription in this segment in comparison to others for anemia caused by renal disorders.
Based on the Application, the Global Erythropoiesis Stimulating Agents Market classified into Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases, and others. The Cancer segment anticipated to dominate the market as the patients with cancer-related anemia is commonly prescribed by erythropoietin in the form of epoetin alfa and epoetin beta. Renal Disorders segment will grow by renal anemia, which predominantly rises due to relative erythropoietin (EPO) deficiency.
Based on the distribution channel, the Global Erythropoiesis Stimulating Agents Market segmented into Offline Channel and Online Channel. The Offline Channel segment will dominate the market due to population, which is still dependent on conventional distribution channels such as pharmacies at the hospital, ambulatory surgical centers, and retail pharmacies. Online Channels will drive by the rising number of internet users and the availability of online platforms to purchase pharmaceutical products.
Based on geography, the global Erythropoiesis Stimulating Agents market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America expected to dominate the market attributed to the availability of effective treatments for various chronic diseases, like cancer, chronic kidney disease (CKD), neural, and HIV infections, along with increasing investments in the R&D activities from both government and private entities. According to the CDC, in 2016, about 29 million people had diabetes, while about 86 million were in the pre-diabetic stage.
The European market will drive by the emerging economies and new products with better efficacy, which will be a significant opportunity for the erythropoietin stimulating agents market.
Companies such as Biocon, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Biosidus, Thermo Fisher Scientific, F. Hoffmann La Roche, Pfizer, and Ranbaxy Laboratories Ltd are the key players in the Global Erythropoiesis Stimulating Agents Market.
|Market size value in 2020||USD 12.5 Billion|
|Revenue forecast in 2027||USD 20.3 Billion|
|Growth Rate||CAGR of 10.30% from 2020 to 2027|
|Forecast period||2021 – 2027|
|Region covered||North America, Europe, Asia-Pacific, South America, and Middle East & Africa|
|Key companies Profiled||Biocon, Johnson & Johnson, F. Hoffmann La Roche, Pfizer,|
Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche,
Teva Pharmaceutical Industries Ltd., Biosidus, Thermo Fisher Scientific,
and Ranbaxy Laboratories Ltd.
By Product Type
By Distribution Channel
Erythropoiesis Stimulating Agents is a substance secreted by the kidneys and liver that stimulates the bone marrow to make more red blood cells.
Erythropoiesis-stimulating agents are used to treating anemia caused by chronic kidney failure (CKD), some anticancer drugs, and certain treatments for HIV.
The global erythropoiesis-stimulating agents market is projected to generate revenue over USD 12.5 Billion by 2020.
The Global Erythropoiesis Stimulating Agents Market is growing at a CAGR of 10.30% during the predicted period, 2021-2027.
The increasing number of patients suffering from anemic conditions induced due to cancer, HIV, and kidney failures, rise in the incidence of tumor-related anemia, Rising awareness about erythropoiesis-stimulating agent therapies are the drivers of the global erythropoiesis-stimulating agents market.